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A REVIEW OF METFORMIN AND OLANZAPINE

Abstract
This review explores the case of a young Native American male who has been newly
diagnosed with schizophrenia. The course of his mental illness is examined as it relates to his
first psychotic episode. Furthermore, the adverse weight gain this patient experiences after
beginning olanzapine therapy is examined. This clinical problem necessitates the need for
providers to address this metabolic issue through prevention or early treatment. A literature
review was conducted with the objective to explore efficacy of metformin therapy to reduce
weight in adult patients (ages 18-64) diagnosed with schizophrenia using olanzapine. The
general consensus of the literature recommended use of metformin to prevent weight gain or
reduce weight in patients with schizophrenia using antipsychotics. Metformin was mostly well
tolerated by patients with minimal side effects and patients demonstrated good adherence.
Metformin initiated early into antipsychotic therapy was associated with less weight gain.
Literature on use of metformin in patients on olanzapine is limited and more research is needed
to guide practice.
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Background
Second generation antipsychotics (SGAs or atypical neuroleptics) are currently the
preferred choice of antipsychotics for patients with schizophrenia. These medications are
efficacious and have fewer side effects compared to first generation antipsychotics (FGAs or
typical neuroleptics), which have high incidences of extrapyramidal symptoms
and tardive dyskinesia (Berrahal et al., 2016). However, the incidence of metabolic syndrome is
higher with SGAs than FGAs, which the patient or client often first recognizes by weight gain
(De Silva et al., 2016). Metabolic syndrome is diagnosed when the patient has three or more of
the following manifestations: increased abdominal girth, low high density lipoprotein, elevated
fasting triglycerides, hypertension, and impaired fasting glucose (Meyer et al., 2005). Poorly
managed metabolic syndrome leads to cardiovascular and cerebrovascular disease and
subsequent decreased life span in patients with schizophrenia compared to the general population
(Ongur, 2016). Evidence of development of metabolic syndrome was well established in the
landmark National Institute of Mental Health (NIMH) Clinical Antipsychotic Trials of
Intervention Effectiveness (CATIE) study. The findings of this study and numerous studies on
antipsychotic associated weight gain (AAWG) that have followed raises the need for providers to
monitor for the development of metabolic syndrome and limit morbidity that ensues in patients
with schizophrenia.
Olanzapine (Zyprexa) is a SGA widely used in the management of schizophrenia, though
is notable for significant weight gain (Baptista et al., 2007). In fact, olanzapine and clozapine
(Clozaril) have the highest propensity for weight gain among all antipsychotics (Dayabandara et
al., 2017). AAWG is a major cause of lack of adherence to treatment, which subsequently leads
to increase in relapse, longer hospital stays, and functional impairment (Meyer et al., 2005).
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According to Wu et al. (2008a), 70% of weight gain from olanzapine is observed in the first 12
weeks of therapy and plateaus around 39 weeks. Providers have the option of switching patients
to a more weight neutral antipsychotic, however olanzapine is highly effective in the treatment of
schizophrenia and has low rates of discontinue compared to other antipsychotics. In addition,
providers risk relapse with switching and increase the likelihood of discontinuation of
antipsychotic therapy (Dayabandara et al, 2017). This poses a treatment challenge for providers
managing these patients who may otherwise be experiencing good effect from olanzapine
therapy.
Metformin is an oral anti-diabetic that is widely used in psychiatry in the management of
AAWG for its safety, tolerability, high levels of adherence, and efficacy for metabolic control
(Baptista et al., 2007). Metformin increases insulin sensitivity, suppresses appetite, and treats
obesity (De Silva, 2016). Because it does not cause hypoglycemia or require monitoring,
metformin is an easy addition to a patient’s medication regimen. However, available research on
AAWG is incongruent in their findings, which state metformin prevents weight gain, reverses
weight gain, or has no effect at all (Hoffman, Case, & Jacobson, 2012).
According to Ongur (2016), concern for the increased risk for suicide, homicide, and
lethal accidents in patients with schizophrenia compared to the general population is given more
attention than necessary because this only represents a small portion of the population. Instead,
Ongur (2016) asserts that attention should be redirected to the increase risk for cardiovascular
and cerebrovascular morbidity and mortality in patients with schizophrenia. This population lives
an average of 20 years less than the general population, which is believed to be due to metabolic
syndrome caused by antipsychotic therapy (Ongur, 2016). This investigation aims to explore the
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efficacy of metformin therapy to reduce weight in adult patients diagnosed with schizophrenia
using olanzapine therapy.

Case Report
BD is a Native-American male who was first seen in office February 2017 at age 17
accompanied by his mother. On intake longstanding mental illness was evident based on patient
and mother’s report. Mother reports that patient was born at 36 weeks without complications and
met his developmental milestones. BD has a history of physical abuse by his baby sitter at age
nine and now experiences nightmares and flashbacks. At age ten BD’s parents divorced, which
introduced new stressors to his life, such as having to move often and seeing his dad
infrequently. On intake BD reports he has one or two friends at school, eats lunch alone, chooses
not to talk to others, and worries about scrutiny. He identifies as gay and struggles with his
sexuality as he has not disclosed this to anyone until today. Depression was evidenced by low
motivation, poor academic performance, self-injurious behaviors (cutting), and thoughts he
would be better off dead. He admits to daily marijuana use and was encouraged to abstain due to
negative influence on his mood. Furthermore, mother shares she notices BD has been more
withdrawn. Initial diagnoses for BD were Major Depressive Disorder, moderate to severe,
Unspecified Anxiety Disorder, and Cannabis Use Disorder. At this time patient was started on
escitalopram (Lexapro) to target depressive and anxious symptoms.
After the initial consult BD and his mother struggle with making it to scheduled
appointment and are not seen in office for three months. During this time BD attempted suicide
in March 2017 for the first time by overdose on escitalopram (Lexapro). Suicide attempt is
notable for occurring within a month of beginning escitalopram (Lexapro) therapy, which comes
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with a Food and Drug Administration (FDA) Black Box warning for increasing suicidality in
children adolescents, and young adults (Epocrates, 2018). BD had is first inpatient mental health
hospitalization for medication adjustments and crisis intervention. He was discharged to a mental
illness and chemical dependency (MICD) dual diagnosis day treatment program.
BD and his mother continue to struggle with follow up on mental health services and
patient is not seen in office again for an extended period. During this time he had another
inpatient mental health hospitalization after his first psychotic episode in August 2018 at age 19.
BD was brought into the emergency department (ED) by an off duty officer after being noted to
be walking barefoot at night and exhibiting bizarre behavior. While in the ED he was endorsing
persecutory delusions of his parents trying to kill him. He was admitted to the inpatient mental
health unit where his thought process continued to be grossly disoriented as evidenced by reports
of persecutory delusions and visual hallucinations. During this hospitalization BD was MICD
committed with a Jarvis through Hennepin County, provisionally discharged, and assigned a case
manager.
Ascertaining a diagnosis is difficult for BD, which is further complicated by the fact he
had infrequent contact with mental health services. It is unclear how long he was experiencing
hallucinations, delusions, or other cardinal symptoms of schizophrenia. Substance induced
psychotic disorder is also on the differential, however also cannot be diagnosed with certainty
without knowing onset of his symptoms. Furthermore, schizoaffective disorder is also a
possibility due to his history of depression. Due to these limitations, Unspecified Schizophrenia
Spectrum Disorder is the most appropriate diagnosis.
BD returned to his outpatient psychiatrist for follow-up with his case manager in
September 2018. During the hospitalization previously discussed, BD was stabilized on a high
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dose of olanzapine at 40 mg daily and per his Jarvis order he was to continue to antipsychotic
therapy. In office BD no longer endorsed delusions, paranoia, or hallucinations. Return to
baseline functioning is evidenced by his ability to return to work his part time job. However,
within three weeks BD gained 30 pounds, going from 153 pounds to 183 pounds. This rapid
weight gain is alarming, because weight gain of more than 5% in the first month is a strong
predictor of long-term weight gain (Dayabandara et al., 2017). In office, a goal was set with the
patient to reduce this dose overtime or switch agents due to concern of rapid weight gain,
development of metabolic syndrome, and subsequent morbidity.
Literature Review
This investigation aims to explore the efficacy of metformin therapy to reduce weight in
adult patients (ages 18-64 years old) diagnosed with schizophrenia using olanzapine
therapy. Electronic databases used for this investigation include PsychInfo, PubMed, Scopus,
and CINAHL. Key terms searched include “olanzapine,” “metformin,” “weight gain,” and
“antipsychotic associated weight gain.” Search results will be limited to adults diagnosed with
schizophrenia and articles published in English. The literature reviewed will include participants
with comorbidities (e.g. anxiety, depression, bipolar disorder). Participants with preexisting
diabetes will be excluded from this review. It is anticipated the findings will indicate metformin
is an effective intervention to reduce weight in non-diabetic patients with schizophrenia on
olanzapine.
This review begins with the work of Dr. Trino Baptista, a physician and researcher from
the University of the Andes in Venezuela, who has done extensive work on the relationship
between antipsychotics and metabolic syndrome. Baptista et al. (2006) took interest in the issue
of olanzapine associated weight gain (OAWG) and conducted a study of metformin use in
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patients taking olanzapine. This is an important study that is referenced by many of the
subsequent studies in this literature review. In a 14-week randomized control trial (RCT), 40
adult inpatients with schizophrenia or schizoaffective disorder on olanzapine were given
metformin 850-1700 mg or placebo daily. Metformin was titrated according to clinical response.
At the end of the study, the investigators did not find metformin to be effective for lowering
body weight. However, the investigators acknowledge the limitations of not having a long
enough intervention period or a large enough sample size.
Dr. Trino Baptista continued to develop this research in 2007 with a larger sample size.
In this study Baptista et al. (2007) successfully found evidence of weight loss in patients on
olanzapine with adjunctive metformin. In another double-blind RCT, 80 participants were
randomly assigned to receive adjunctive metformin 850-2550 mg or placebo in combination with
olanzapine daily for 12 weeks. Titration of metformin to high doses was well tolerated by
participants. The median amount of weight loss in the treatment group was about three pounds.
While a modest decrease in weight, the treatment group lost up to ten pounds at the end of the
12-week trial while the placebo group only maintained weight at the end of this period. While
the length of study time was short, this study can be appreciated for its large sample size and the
majority of the participants had schizophrenia (76 participants). However, this was achieved by
included 60 inpatients and 20 outpatients with schizophrenia in the study, which limits control of
the study.
Baptista et al. (2008) tested the efficacy of treating OAWG with combination therapy.
However, their research found insignificant results with metformin combination therapy with
sibutramine for treatment of OAWG. Originally developed as an antidepressant, sibutramine is a
anorectic agent that decreased appetite and reduces calorie intake used in the treatment of obesity
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(National Institute of Health [NIH], 2018). In this study, 30 inpatient adults with chronic
schizophrenia converted from long-term use of FGAs to olanzapine monotherapy. After
conversion was completed, participants received metformin plus sibutramine or placebo for 12
weeks. The dose of metformin plus sibutramine was gradually increased in the treatment group
from 850 mg to 1700 mg and 10 mg to 20 mg respectively. Metformin and sibutramine was
titrated according to clinical response. The results did not find efficacy in this combination for
treatment of metabolic symptoms and weight loss observed in the treatment group compared to
placebo group was statistically insignificant. Furthermore, it should be noted that since this time
sibutramine has taken off the market due to adverse cardiovascular effects, including increased
blood pressure, increased heart rate, myocardial infarction and stroke (NIH, 2018).
Hoffman, Case, and Jacobson (2012) also proposed use of combination therapy to
prevent or treat OAWG. In a 22-week outpatient setting RCT, 199 participants were given
olanzapine alone, olanzapine plus algorithm A, or olanzapine plus algorithm B. Algorithm A and
B both utilized equivalent doses of amantadine, metformin, and zonisamide, but medications
were scheduled differently. All three medications have had reports of promoting weight loss
(Hoffman, Case, & Jacobson, 2012). Amantadine is primarily used to treat Parkinson’s disease
and extrapyramidal symptoms and zonisamide is primarily used as an anticonvulsant (Hoffman,
Case, & Jacobson, 2012). In algorithm A, olanzapine was given with amantadine with a possible
switch to metformin and then to zonisamide. In algorithm B, olanzapine was given with
metformin with a possible switch to amantadine and then zonisamide. Switches in medications
were made according to the algorithm and determined by rate of weight gain. Participants who
received olanzapine plus algorithm B (where metformin was initiated first) had the least weight
gain. The results of this study demonstrate the benefits for treating OAWG using combination
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therapy based on clinical feedback. These findings support Baptista et al.’s (2008) proposition to
treat OAWG with combination therapy and recommendation to tailor therapy based on clinical
response.
Dr. Ren-Rong Wu, a psychiatrist from China, is another influential investigator who has
led several studies on metabolic syndrome with antipsychotic use. Wu et al. (2008a) tested the
efficacy of metformin on OAWG in 40 antipsychotic-naïve adults. These participants were
newly diagnosed with schizophrenia, starting olanzapine after their first psychotic episode, and
were all in the same stage of their disease. In this 12-week double-blind RCT, olanzapine plus
placebo or olanzapine plus metformin was administered in a highly controlled setting. All
patients ate the same diet, participated in the same exercise regimen, and were not on any other
medications prior to this study for at least three months. Weight gain in the olanzapine plus
placebo group was clinically significant, or 7% of their bodyweight. The effects of metformin in
the treatment group were not robust and suggest prophylactic use of metformin to prevent
OAWG rather than treat obesity that has already developed. Fewer patients on olanzapine plus
metformin gained weight compared to patients who received olanzapine plus placebo, but weight
loss was not observed. The results of this study has strong reliability due to the controls applied
to this inpatient sample. However, generalizability is limited because these controls create an
artificial environment for interpreting the results and limit the ability to apply them to patients in
the community. Nevertheless, these findings have important implications for clinical practice.
Because the study was conducted in young patients who were antipsychotic naïve, we can assess
the effects of olanzapine on metabolic syndrome. Not only did these findings substantiate the
utility of metformin to prevent weight gain, it also demonstrated significant weight gain early in
olanzapine therapy.
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Despite the lack of literature on metformin therapy in patients on olanzapine, there is
good studies that supports the use of metformin in patients with schizophrenia on SGAs, such as
olanzapine. In a larger RCT, Wu et al. (2008b) compared four interventions in 128 adult
inpatients with schizophrenia. Interventions included metformin 750 mg daily alone, placebo
daily, lifestyle interventions alone, or lifestyle interventions plus metformin 750 mg daily for 12
weeks. These patients had gain more than 10% of their predrug weight within the first year of
starting clozapine, olanzapine, risperidone, or sulpiride. Wu et al. (2008b) found that lifestyle
interventions plus metformin 750 mg daily yield the greatest amount of weight loss. However,
the metformin treatment alone led to greater weight loss than lifestyle interventions alone.
Metformin use with AAWG in patients with schizophrenia after their first psychotic
episode was investigated again by Wu et al. (2012) in a longer study. In this double-blind RCT,
84 female outpatients who experienced amenorrhea and AAWG from antipsychotics were
randomly assigned to received metformin 1000 mg or placebo daily for 24 weeks. At the end of
the study 67% of participants in the metformin group both resumed their menstrual cycle and lost
an average of 4.1% of their bodyweight. This was not observed in the placebo group, where only
4.8% of participants resumed their menstrual cycle and gained on average 3.7% of their
bodyweight. Participants in this study were on one of the four following medications: clozapine,
olanzapine, risperidone, or sulpiride. However, the authors do not identify how many participants
were on olanzapine or how they responded to metformin or placebo. Nevertheless, the findings
of this study suggest metformin is effective in promoting weight loss in patients with
schizophrenia and on SGAs, such as olanzapine.
These findings were later reinforced in Wu et al.’s 2016 research that continued to focus
on first-episode patients beginning antipsychotic therapy. The primary investigation of this study
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was to evaluate the efficacy of metformin to treat antipsychotic-induced dyslipidemia in adult
patients with schizophrenia after their first psychotic episode. The authors also measured
bodyweight response to metformin therapy as a secondary outcome measurement. In this study
201 adult patients with schizophrenia were randomly assigned to receive metformin 1000 mg or
placebo daily in a 24-week RCT. Similar to the previous study discussed, participants were on
one of the four following medications: clozapine, olanzapine, risperidone, or sulpiride. 47.8% of
these participants were on olanzapine, however the exact response to metformin or placebo in is
no identified. The authors state that significant weight loss was seen in the metformin group, but
they do not define what is significant or say how much weight lost was measured. The findings
of this study showed weight loss effects were not seen until 12 weeks of treatment and continued
up until the end of the study. The results from this study reiterates the efficacy of metformin to
reduce weight in patients on antipsychotics and supports the need for long term treatment to see
therapeutic effects in patients using SGAs.
Wang et al. (2012) also investigated the effects of metformin on AAWG in adult patients
with schizophrenia after their first episode of psychosis. These participants had already gained a
clinically significant amount of weight, which the authors define as at least 7% of their body
weight, upon entering the study. In this double-blind RCT, 72 adult patients received metformin
1000 mg or placebo daily as an adjunct to a SGA for 12 weeks. Weight loss in the metformin
group was clinically significant. The placebo group continued to gain weight on top of the 7%
clinically significant AAWG. Unlike the previously study, Wang et al.’s (2012) research
included participants on other atypical antipsychotics and only 15 participants were on
olanzapine. However, the findings of this study are significant in this review for a several
reasons. First, it is notable that this study examined the effects of metformin in patients who had
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already gained a clinically significant amount of weight. This is an issue providers often
encounter, because they inherited a patient with metabolic syndrome or preventive measures
were not initiated in a timely manner. In addition, even though not all participants were on
olanzapine, atypical antipsychotics have similar side effect profiles. Therefore providers can use
the findings of this study to make informed decisions for patients afflicted with AAWG or
OAWG.
Similar to Dr. Ren-Rong Wu’s work, Rado & von Ammon Cavanaugh (2016) also found
evidence of treatment-over-time effects observed later into metformin therapy in the treatment of
OAWG. In this double blind RCT of community-dwelling adult patients, 25 adult participants
beginning olanzapine therapy were randomly assigned to receive either adjunctive metformin or
placebo for 24 weeks. In addition to its long study period, control for the influence of other
antipsychotics is also a strength of this study. Patients on antidepressants and mood stabilizers
were included in this study, though use of other antipsychotics within 3 months of the study was
not allowed in this study to fully appreciated the metabolic effects of olanzapine. Metformin
extended release formulation was titrated up to 2000 mg daily or as clinically indicated and was
well tolerated. The results of this study did not demonstrate efficacy of metformin to reduce
weight in patients on olanzapine therapy, but it did show evidence of the ability to prevent
weight gain. At the end of the 24-week trial, the treatment group gained an average of 5.5 pounds
verses 12.8 pounds gained by the placebo group (increases of 3% and 7% of body weight
respectively). The generalizability of this study is limited by its small sample size of 25
participants. Furthermore, it should be noted that patients with schizophrenia, schizoaffective
disorder, bipolar disorder, and major depression with psychotic features were all include in this
study.

A REVIEW OF METFORMIN AND OLANZAPINE

15

De Silva et al.’s (2015) study on metformin therapy in adult patients with schizophrenia
or schizoaffective disorder also suggested treatment over longer periods of time. These
participants had already been afflicted with AAWG and had gained more than 10% of their
bodyweight from SGAs. In an outpatient, double blind RCT, 66 South Asian patients received
metformin 500 mg or placebo twice a day for 24 weeks. While not robust, the findings of this
study indicate metformin can be used to reduce bodyweight in patients with schizophrenia or
schizoaffective disorder and on a SGA. At the end of the study, the metformin group on average
lost 1.84% of their bodyweight whereas the placebo group gain 1.4% of their bodyweight.
However, only 18 participants of this study were on olanzapine and only ten participants were in
the metformin group. In addition, several articles in this review indicate a 7% change in
bodyweight is clinically significant and none of the participants of this study lost more than 5%
of their bodyweight. Furthermore, the authors acknowledge that weight loss could be influenced
by the East Asian ethnicity of participants. Nevertheless, this study is remarkable for its long
study period which showed evidence of a significant time-by-treatment interaction with
metformin use. Significant weight loss was not seen until 2-3 months after treatment was
initiated, which suggest that some of the studies in this review may not have been long enough to
fully appreciate the effects of metformin.
Jarkskog et al. (2013) also found evidence of a time-by-treatment effect with metformin
use. Jarkskog et al. (2013) investigated the efficacy of metformin to promote weight loss in
overweight adult patients with schizophrenia. Overweight was defined as a body mass index
(BMI)  27. In this double blind RCT, 148 outpatients received metformin or placebo for 16
weeks. At the end of the study, participants in the treatment group lost a mean average of 2.8%
of their bodyweight compared to 1% loss in the placebo group. Unfortunately the authors do not
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specify what medications the patients are on and only state the patients were receiving one or a
combination of two FDA-approved antipsychotics. In addition, confounding factors of this study
include weekly diet and exercise counselling that likely promoted the observed weight loss.
However, this study does offer evidence that there is utility in use of metformin to reduce weight
in overweight patients with schizophrenia on antipsychotics.
All literature in this review was Level II evidenced based on Melnyk and FineoutOverholt’s rating system for the hierarchy of evidence. The strengths and limitations throughout
the literature varied, but all of the RCTs of this review were well-designed. The investigators
established clinical relevance of their investigation well and posed their hypothesis clearly. All
studies were placebo controlled. All but two studies used double blinding. Four studies cited
using an independent party to sort and distribute medications to ensure concealment. Methods of
randomization were well executed and all but two studies employed random allocation via
computer based generator.
The literature consistently stated metformin had clinical utility for OAWG or AAWG.
All articles in this review stated that metformin either prevented OAWG or AAWG or reduced
body weight in patients using SGAs. Length of the studies in this review ranged from 12 weeks
to 24 weeks. Three of the studies suggested metformin therapy becomes more efficacious over
time. This review studied patients at different stages of schizophrenia. Four of the studies
showed evidence of preventing onset of OAWG or AAWG in patients after their first psychotic
episodes and newly beginning antipsychotic therapy. The two studies that did not find efficacy in
reducing body weight with metformin are notable for having patients who had been on long-term
antipsychotic therapy. This further supports the idea that metformin is useful for prevention of
weight gain, rather than treating weight gain that has already manifested. Research design could
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not eliminate the influence confounding factors, such as genetics or lifestyle choices, which
inherently compromise with results in these studies. Furthermore, it was consistent throughout
the literature that metformin was safe to use, mostly well tolerated, and patients had high levels
of adherence to treatment. Participant drop out was often cited to be due to gastrointestinal side
effects. Many of these side effects could be alleviated by dose adjustment or resolved after
discontinuation of metformin.
Implications
Stakeholders of this clinical challenge include adult patients with schizophrenia on
olanzapine, primary care providers (PCP), and psychiatric-mental health (PMH) providers. The
PMH provider’s objective in managing care for these patients should be remission of symptoms
with minimal adverse effects. It is imperative for PCPs and PMH providers to take an active role
in preventing and treating metabolic syndrome in this population. The high incidence of
metabolic syndrome in patients taking olanzapine presents a learning opportunity for PCPs and
PMH providers. Based on the this literature review, metformin should be used adjunctively in all
patients with schizophrenia using SGAs, such as olanzapine. In addition, providers should be
educated on evidence of weight gain early into olanzapine therapy, which should influence
providers to initiate metformin therapy as a preventative measure. Education on adjunctive
metformin use with olanzapine should also include education about metabolic monitoring for
these patients. This should include monitoring bodyweight, waist circumference, BMI, blood
pressure, fasting glucose, and a fasting lipid panel throughout the course of SGA therapy.
Furthermore, providers managing olanzapine should be considering the need to refer the patient
to a specialist should metabolic syndrome advance. This education can be implemented in the
work place as a part of mandatory education that offers continue education units (CEUs) to
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providers. Tip sheets that concisely outlines monitoring parameters can also be distributed
throughout hospitals or clinics where patients on olanzapine are being managed.
This review also raises the need for further education in patients with schizophrenia on
olanzapine and their support systems (e.g. families, caregivers, community-based mental health
facility staff). These parties should be informed of weight gain trends early in treatment and how
to monitor for its possible development. This information should include how to accurately
monitor weight, abdominal girth, and the importance of regular physicals to evaluate overall
metabolic condition. Patient education on weight management, dietary considerations, exercise,
and lifestyle modifications to promote a healthy weight should also be provided and reinforced at
every encounter with the PMH provider and the PCP. Providers should identify and address
barriers to implementing these interventions and problem solve with the patient to work around
these barriers. In addition, providers should educate these parties on the benefits and limitations
of adjunctive metformin on OAWG and the prospect of improved outcomes if combined with
lifestyle modifications. Furthermore, education should address side effects of metformin and the
ability to manage them with dose adjustments to encourage adherence.
Literature on use of metformin in patients on olanzapine is limited and more research is
needed to guide practice. For this reason, this review includes literature greater than 10 years.
Expanding the scope of this investigation to include studies on SGAs provides greater insight on
the influence of metformin to treat weight gain. There is a need for replication studies to validate
these findings and incorporate them into practice. These replication studies need to be longer
term, need to be conducted in larger sample sizes, and participants should be more homogenous
(e.g. all first-episode, all long-term olanzapine users, patients within a certain BMI range,
narrower range of age). The findings of the literature is summarized in Table 1.
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Table-1
Author
Baptista et
al. (2006)

Design
Doubleblind RCT

Baptista et
al. (2007)

Doubleblind RCT

Baptista et
al. (2008)

De Silva
(2015)

Clinical
trial

Doubleblind RCT

Study sample
n=40
Adult outpatients
and inpatients
with schizophrenia
or schizoaffective
disorder on
olanzapine
n=80
Adult inpatients
with schizophrenia
or bipolar on
olanzapine

Intervention
Received
metformin 8501700 mg or
placebo daily for
14 weeks

Strengths
• Double
blinding
• Randomization
• Only evaluated
olanzapine

Received
metformin 8502550 mg daily or
placebo for 12
weeks

•

n=30
Adult inpatients
with chronic
schizophrenia who
switch from longterm conventional
antipsychotics to
olanzapine

Received
metformin (8501700 mg) plus
sibutramine (1020 mg) or
placebo twice a
day for 12 weeks

•

n=66
Adult South Asian
outpatients with
chronic

Received
metformin 500
mg or placebo
twice a day for

•
•

•
•

•
•
•

Limitations
Findings
• Short study
• Metformin did not prevent
time
weight gain in patients
using olanzapine
• Small sample
size
• Outpatient and
inpatient sample

Double
•
blinding
Randomization
Only evaluated •
olanzapine

Includes
patients with
bipolar disorder
Short study
time

•

On olanzapine •
monotherapy
for at least 4
•
months before
start
Randomization
Only included
patients with
schizophrenia

Short study
time
Small sample
size

•

Double
•
blinding
Randomization
•
Long study

Only 15 of 66
participants on
olanzapine
Participants

•

•

•
•
•

Metformin group lost
weight and placebo group
maintained weight
Metformin is safe, well
tolerated, and can be used
to reduce weight
Weight loss observed with
intervention, but not
clinically significant
Weight loss with
metformin plus
sibutramine not superior to
metformin alone
GI upset noted from
metformin plus
sibutramine
Metformin effective for
reducing weight
Significant time-bytreatment effect (lag time
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Hoffman,
Case, &
Jacobson
(2012)

RCT

Jarskog et
al. (2013)

Doubleblind RCT

Rado &
Von
Ammon
Cavanaugh
(2016)

Doubleblind RCT

schizophrenia or
schizoaffective
disorder afflicted
with AAWG
n=199
Adult outpatients
with schizophrenia
or schizoaffective
disorder

n=148
Adult overweight
outpatients with
chronic
schizophrenia or
schizoaffective
disorder

n=25
Adult outpatients
with
schizophrenia,
schizoaffective
disorder, bipolar
disorder, or major
depression with
psychotic features

24 weeks

Received
olanzapine alone,
olanzapine plus
algorithm A, or
olanzapine plus
algorithm B for
22 weeks. See
literature review
for details
Received
metformin 500
mg or placebo
twice a day for
16 weeks

Received
olanzapine plus
metformin or
olanzapine plus
placebo for 24
weeks

•
•
•

•
•
•

•

•
•
•
•

time

could be on one
or more
antipsychotics

of 2-3 months)

Long study
•
time
Randomization
Only evaluated
olanzapine

Included use of •
other
medications not
of interest in
this review
•
(amantadine
and zonisamide)

Double
•
blinding
Randomization
Large sample
•
size

Does not tell
what
antipsychotics
patients are on
Patients could
be on any one
or two
antipsychotics
to participate
Included other
diagnoses that
are not of
interest in this
review
Small sample
size
Length of study

Participants who received
metformin earlier in
treatment had less weight
gain
Suggest combined therapy
and algorithm is more
effective than
monotherapy and standard
treatment for weight loss
Metformin was modestly
effective in reducing
weight
Significant time-bytreatment effect
Metformin was mostly
well tolerated and side
effects were minimal

Naturalistic
•
sample in a
community
setting
Long study
time
•
Double
•
blinding
Randomization
Only evaluated
olanzapine

•
•
•

•
•
•

Weight loss observed with
metformin was no robust
Metformin is good for
prevention of weight gain
Metformin is well
tolerated
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Wang et al.
(2012)

Wu et al.
(2008a)

Wu et al.
(2008b)

Doubleblind RCT

Doubleblind RCT

RCT

n= 72
First episode
schizophrenia who
gain more than 7%
of their predrug
weight

n=40
Adult inpatients
with schizophrenia
after first-episode
psychosis who
were antipsychotic
naïve and already
gained more than
7% of their
predrug weight
n=128
Adult inpatients
with schizophrenia
who gained more
than 10% of their
predrug weight

Received
metformin 1000
mg daily or
placebo for 12
weeks

•
•
•

Receive
olanzapine plus
metformin 750
mg daily or
olanzapine plus
placebo for 12
weeks

•

Receive one of
four treatments:
metformin 750
mg daily,
lifestyle
intervention,
placebo, or
lifestyle
intervention plus

•
•

•
•
•

Randomization •
Large sample
size
•
Only included
patients with
schizophrenia
•

Double
•
blinding
Randomization •
Only evaluated
olanzapine
Only included
patients with
schizophrenia
Randomization •
Large same
size

Short study
time
Does not
describe
randomization
process
Included
patients on
medication not
of interest in
this review
(clozapine,
risperidone,
sulpiride)
Small sample
size
Short study
time

•

Included
patients on
medication not
of interest in
this review
(clozapine,
risperidone,
sulpiride)

•

•
•

•
•

Weight loss observed in
the metformin group was
clinically significant
Metformin was mostly
well tolerated and has
good adherence
Decrease in weight noted
at 8 weeks and continued
through the end of the
study

Metformin effective for
weight loss for OAWG or
as a preventive measure
Metformin was well
tolerated and had good
adherence

Lifestyle interventions
plus metformin showed
the most weight loss in
AAWG. However,
metformin alone was
superior to lifestyle
intervention alone for
reducing body weight.
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Wu et al.
(2012)

Wu et al.
(2016)

Doubleblind RCT

Doubleblind RCT

n=84
Adult outpatient
Chinese women
diagnosed with
schizophrenia
after their first
psychotic episode
who were afflicted
with amenorrhea
n=201
Adults with
schizophrenia
diagnosed with
antipsychoticinduced
dyslipidemia

metformin for 12
weeks
Received
metformin 1000
mg or placebo
daily for 24
weeks

Received
metformin 1000
mg or placebo
daily for 24
weeks

•
•
•

•
•
•

Double
•
blinding
Randomization
Long study
time

Included
patients on
medication not
of interest in
this review
(clozapine,
risperidone,
sulpiride)

•

Double
•
blinding
Randomization
Long study
time

Included
patients on
medication not
of interest in
this review
(clozapine,
risperidone,
sulpiride)

•

•

•

Metformin promoted
weight loss, but weight
loss observed was not
clinically significant
Metformin restored
menstrual cycle

Metformin led to clinically
significant weight loss
Time-by treatment effect
observed
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